Previously, we demonstrated the potential of obestatin, a peptide derived from preproghrelin, and the G‐protein coupled receptor, GPR39 (the obestatin/GPR39 system), as therapeutic target for muscle injury and myopathies related to skeletal muscle regeneration [30, 31, 32]. Here, GPR39 is linked to myopathy.